# ABM Respiratory Care

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/abm-respiratory-care

- Industry: Medical Devices & Equipment
- Headquarters: Eagan, US
- Website: www.abmrc.com
- Total disclosed funding: $35M
- Latest round: Growth (Oct 20, 2026)
- Investors on record: 2

## About

ABM Respiratory Care is a Singapore-based company specializing in innovative respiratory care solutions, focusing on enhancing patient monitoring and treatment through advanced ventilator technology.Founded in 2017 in the US, ABM Respiratory Care develops advanced respiratory solutions, including their flagship product, the Alpha Ventilator. The company has successfully raised a total of USD 10.65 mn through Series A funding led by Advanced MedTech Holdings and SEEDS Capital. The CEO of the company is Gregory Miller, and among the founders are Chad Boerst and Vinay Joshi. The most recent investment round occurred on November 25, 2021, contributing to a valuation of USD 30.569 mn.ABM Respiratory Care specializes in advanced respiratory solutions, with a primary focus on their flagship offering, the Alpha Ventilator. This state-of-the-art device integrates telehealth technology, enabling healthcare professionals to monitor and program multiple ventilators remotely, thereby enhancing patient care while minimizing exposure to infectious environments. The ventilator employs advanced turbine technology, allowing for various therapy modes that cater to both invasive and non-invasive ventilation needs. Designed for versatility, the Alpha Ventilator is suitable for a broad range of patients, including both pediatric and adult populations, and is utilized across various settings such as hospitals, skilled nursing facilities, and home care environments. The company also offers products like BiWaze Clear and BiWaze Cough, which aim to improve respiratory therapy and are marketed to healthcare providers, caregivers, and patients throughout North America and select international markets.ABM Respiratory Care generated revenue of USD 2,549,542 in the year 2022. The company reported an EBITDA of USD -2,631,364 for the same year. Revenue is primarily derived from direct sales of its respiratory devices and solutions to healthcare facilities and professionals, operating on a B2B transaction structure.The company plans to leverage its recent funding from the Series A round to develop and launch new products, enhancing their existing line of respiratory solutions. They are targeting specific geographic regions for expansion, with plans to enter new markets by the end of 2023. Funding will support these initiatives, enabling the design and introduction of innovative products to strengthen their market position and reach a broader clientele.

## Funding rounds

- Growth, Oct 20, 2026, $20M — Trinity Capital Inc.
- Series B, Jun 17, 2025, $15M — Bluwave Capital LLC

## Investors

- Bluwave Capital LLC (https://capitalatlas.ai/funds/bluwave-capital-llc) — Series B
- Trinity Capital Inc. — Growth